A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

NCT06025344 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Relative Bioavailability

Interventions

DRUG: PanCytoVir™ 100 mg/mL oral suspension
DRUG: Probenecid 500 mg

Sponsor

TrippBio, Inc.